

Masaki Kanazu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9290683/publications.pdf>

Version: 2024-02-01

12
papers

335
citations

1307594

7
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

662
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight, 2018, 3, . | 5.0 | 156 |
| 2 | Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. Lung Cancer, 2017, 109, 42-44. | 2.0 | 47 |
| 3 | Case series of pleomorphic carcinomas of the lung treated with nivolumab. Thoracic Cancer, 2017, 8, 724-728. | 1.9 | 39 |
| 4 | Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. Thoracic Cancer, 2018, 9, 1782-1787. | 1.9 | 23 |
| 5 | Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PLoS ONE, 2019, 14, e0220570. | 2.5 | 20 |
| 6 | Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. Thoracic Cancer, 2020, 11, 3317-3325. | 1.9 | 20 |
| 7 | Histologic transformation of epidermal growth factor receptor-mutated lung cancer. European Journal of Cancer, 2022, 166, 41-50. | 2.8 | 10 |
| 8 | Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer, 2020, 21, e592-e596. | 2.6 | 5 |
| 9 | Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study. Thoracic Cancer, 2021, 12, 90-96. | 1.9 | 5 |
| 10 | Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. Thoracic Cancer, 2022, 13, 2450-2458. | 1.9 | 4 |
| 11 | EGFR mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. Thoracic Cancer, 2021, 12, 1441-1444. | 1.9 | 3 |
| 12 | Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report. Thoracic Cancer, 2021, 12, 1935-1939. | 1.9 | 3 |